trastuzumab,tucatinib
Seagen,Roche
['mountaineer', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'tucatinib']
 additional analyses of mountaineer in her2# coloncarcinoma at #emso22 tucatinib &amp; trastuzumab arm c: tuc mono -&gt; orr 3% crossover to tuc &amp; tras -&gt; orr 18% dual concurrent her2 blockade key for efficacy -&gt; orr 38% 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision medicine